President, Dorset Capital, LLC
James E. Burden has over 40 years of experience in corporate finance, law practice, and business operations and is President and majority owner of Dorset Capital, LLC.
Mr. Burden’s involvement with co-founding, financing and operating companies in the U.S. and United Kingdom commenced in the 1980s when he was elected an Underwriting Member/Name of Lloyd’s of London. Through his Lloyd’s connections in the City of London, he began working with Small and Medium Enterprises in the U.K.
is assisting Par Equity, a UK-based venture capital firm, expand to the
United States. The first focus area will be investing in digital health
Par Equity USA expanding Par Equity, a UK-based venture capital firm
founded in 2009, to the United States. The second focus area will be the
Par Transatlantic HealthTech Fund I (the “Fund”) investing in digital
health technology companies with proprietary products that are, or are
close to, generating revenue where transatlantic expansion can
accelerate the next stage of their growth. Digital technologies provide
new solutions to address the increasing costs of healthcare and develop
more cost-effective models of personalized patient medical care.
HealthTech includes patient monitoring, wearable medical devices,
robotics, diagnostics and imaging, secure data management and genomic
screening. The Fund will focus on companies suitable for expansion from
the U.K. to the U.S. and companies expanding from the U.S. to the U.K.
Transatlantic expansion is a milestone that can trigger a valuation
inflection and significant returns to the Fund.
In 2001, Mr. Burden was a founding director of EuroGen
Pharmaceuticals Ltd., a U.K. company formed to seek European regulatory
approvals of a NASDAQ-listed company’s drug portfolio. He also was a
founding director of Gloucestershire Innovation Centre, which was formed
to develop and manage incubation facilities in the Bank of England’s
Southgate House in the center of Gloucester, England. Partners included
St. John’s College Cambridge Innovation Centre, the University of
Gloucestershire, and HSBC Bank.
In 2005, he was a founding director of Emiliem, Inc., a Delaware corporation. Emiliem, Inc is a private biotechnology company currently focused on all aspects of the drug discovery and development process. This includes understanding the molecular determinants of target modulation as it relates to the efficacy of therapeutics and to potential adverse drug reactions, and diagnostic markers for rare diseases and the computational aspects of predicting both positive and negative patient outcomes.
Burden received a B.S. degree from the School of Business
Administration, University of California, Berkeley (Haas School of
Business), a J.D. degree from the University of California, Hastings
College of Law, and did post-J.D. studies at the Graduate School of Law,
University of Southern California. He is an active member of the
California State Bar, a member of The Faculty Club, University of
California, Berkeley, and a Fellow of the Institute of Directors,